TheraTech Inc. announced Monday that it has modified its researchcollaboration with Solvay Pharmaceuticals Inc. in the field of femalehormone replacement therapy (HRT).

As a result of the new collaboration, TheraTech (NASDAQ:THRT) ofSalt Lake City has reacquired worldwide rights to its estradiol andcombination estradiol/progestin transdermal delivery products.Solvay now gets U.S. rights for two new female HRT products forwhich an investigational new drug application (IND) was filed onAug. 16.

TheraTech's proprietary estradiol product is in Phase II clinical trials,and the company expects to take the drug into Phase III by the endof the year. The company also said it plans to file an IND for theestradiol/progestin combination patch by the fourth quarter.

(c) 1997 American Health Consultants. All rights reserved.